Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to ...
Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback